Suresh K. Durgam has sold ITCI and made no open-market buys since Jan 2021

EVP and Chief Medical Officer at Intra-Cellular Therapies, Inc.

SEC CIK 0001829958 · Filings on SEC.gov ↗

$0Bought

$10.1MSold

NoneLast buy

Every filing

16 filings since Jan 2021, newest first

ITCISell

Intra-Cellular Therapies, Inc.

EVP and Chief Medical Officer

$673K−34.0%Mar 11

ITCISell

Intra-Cellular Therapies, Inc.

EVP and Chief Medical Officer

$289K−30.0%Feb 27

ITCISell

Intra-Cellular Therapies, Inc.

EVP and Chief Medical Officer

$414K−52.0%Feb 5

ITCISell

Intra-Cellular Therapies, Inc.

EVP and Chief Medical Officer

$4.4M−100.0%Jan 4

ITCISell

Intra-Cellular Therapies, Inc.

EVP and Chief Medical Officer

$1.4M−100.0%Dec 15

ITCISell

Intra-Cellular Therapies, Inc.

EVP and Chief Medical Officer

$120K−8.0%Jul 20

ITCISell

Intra-Cellular Therapies, Inc.

EVP and Chief Medical Officer

$331K−24.0%Mar 13

ITCISell

Intra-Cellular Therapies, Inc.

SVP and Chief Medical Officer

$373K−25.0%Feb 27

ITCISell

Intra-Cellular Therapies, Inc.

SVP and Chief Medical Officer

$391K−27.0%Feb 22

ITCISell

Intra-Cellular Therapies, Inc.

Chief Medical Officer

$452K−26.0%Mar 4

ITCISell

Intra-Cellular Therapies, Inc.

Chief Medical Officer

$211K−11.0%Feb 25

ITCISell

Intra-Cellular Therapies, Inc.

Chief Medical Officer

$231K−13.0%Feb 23

ITCISell

Intra-Cellular Therapies, Inc.

Chief Medical Officer

$262K−21.0%Jan 20

ITCISell

Intra-Cellular Therapies, Inc.

Chief Medical Officer

$280K−19.0%Jan 11

ITCISell

Intra-Cellular Therapies, Inc.

Chief Medical Officer

$107K−11.0%Feb 22

ITCISell

Intra-Cellular Therapies, Inc.

Chief Medical Officer

$140K−20.0%Jan 12

Filings come from SEC EDGAR. Not investment advice.